UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

/PRNewswire/ -- UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis...

Related Keywords

China ,Norway ,Japan ,Denmark ,Brussels ,Bruxelles Capitale ,Belgium ,Daphne Teo ,Charl Van Zyl ,Jim Baxter ,Iris Loew Friedrich ,Antje Witte ,Laurent Schots ,Neurology Head Of Europe International ,Us Communications ,American Association Of Neuromuscular Electrodiagnostic Medicine ,Brand Communications ,Twitter ,European Commission ,Drug Administration ,Corporate Communications ,European Union ,Myasthenia Gravis Foundation Of America ,European Medicines Agency ,Lancet Reg Health West Pac ,Source Ucb Inc ,American Association ,Electrodiagnostic Medicine ,Myasthenia Gravis Foundation ,Scientific Session ,Executive Vice President ,Chief Medical Officer ,Mycaring Phase ,Myasthenia Gravis Activities ,Daily Living ,Quantitative Myasthenia Gravis ,Myasthenia Gravis Composite ,Clinical Trials ,Executive Vice President Neurology ,International Markets ,Generalized Myasthenia Gravis ,Myasthenia Gravis Quality ,Myasthenia Gravis ,Rare Diseases ,Euronext Brussels ,Associated Myasthenia Gravis ,Clinical Features ,Reg Health West ,Gravis Foundation ,Clinical Overview ,Subjects With Generalized Myasthenia Gravis ,Accessed August ,Test Efficacy ,Ucb ,Nc ,